Par launches generic Pylera

Par, an Endo company, is offering the first generic version of Allergan's Pylera (bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride) 40 mg, 125 mg and 125 mg capsules.

"We're proud to be a reliable, quality supplier providing choices to healthcare professionals and their appropriate patients," said Scott Sims, senior vice president and general manager of injectable solutions and generics at Endo. "This first-to-market generic product strengthens our portfolio and is a lower-cost option for people who need the medication."

[Read more: Par releases generic Kuvan]

Bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules, combined with omeprazole, are indicated for treating patients with Helicobacter pylori infection and duodenal ulcer disease (active or history of within the past five years) to eradicate H. pylori.

Pylera had a market value of roughly $30 million for the 12 months ended Dec. 31, 2022, according to IQVIA.

[Read more: Endo acquires Nevakar’s injectable product candidates]